Theralase Technologies Inc
XTSX:TLT

Watchlist Manager
Theralase Technologies Inc Logo
Theralase Technologies Inc
XTSX:TLT
Watchlist
Price: 0.3 CAD 3.45% Market Closed
Market Cap: 72.8m CAD
Have any thoughts about
Theralase Technologies Inc?
Write Note

Theralase Technologies Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Theralase Technologies Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Theralase Technologies Inc
XTSX:TLT
Total Liabilities & Equity
CA$3.4m
CAGR 3-Years
-25%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
Titan Medical Inc
TSX:TMD
Total Liabilities & Equity
$4.5m
CAGR 3-Years
-58%
CAGR 5-Years
-27%
CAGR 10-Years
-20%
Profound Medical Corp
TSX:PRN
Total Liabilities & Equity
$50m
CAGR 3-Years
-19%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Total Liabilities & Equity
CA$50.8m
CAGR 3-Years
17%
CAGR 5-Years
17%
CAGR 10-Years
17%
Nanalysis Scientific Corp
XTSX:NSCI
Total Liabilities & Equity
CA$53.8m
CAGR 3-Years
31%
CAGR 5-Years
38%
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Total Liabilities & Equity
CA$6.4m
CAGR 3-Years
20%
CAGR 5-Years
87%
CAGR 10-Years
14%
No Stocks Found

Theralase Technologies Inc
Glance View

Market Cap
71.8m CAD
Industry
Health Care

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.

TLT Intrinsic Value
0.96 CAD
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Theralase Technologies Inc's Total Liabilities & Equity?
Total Liabilities & Equity
3.4m CAD

Based on the financial report for Jun 30, 2024, Theralase Technologies Inc's Total Liabilities & Equity amounts to 3.4m CAD.

What is Theralase Technologies Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-2%

Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Theralase Technologies Inc have been -25% over the past three years , -2% over the past five years , and -2% over the past ten years .

Back to Top